Characterizing Safety and Clinical Outcomes Associated with High-Dose Micafungin Utilization in Patients with Proven Invasive Candidiasis
Open Access
- 3 February 2022
- journal article
- research article
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 7 (2) , 23
Abstract
Micafungin is the empiric antifungal agent of choice for the treatment of invasive candidiasis (IC). Pathophysiologic changes that occur in obese and/or critically ill patients can alter micafungin serum concentrations and the probability of target attainment. Although high doses of micafungin have been shown to be safe, clinical outcomes have not been widely evaluated. We conducted a single-center, retrospective observational study evaluating safety and clinical outcomes among adult patients treated with ≥200 mg of micafungin for ≥3 days for proven IC from 1 September 2013 through 1 September 2021. Twenty-three unique encounters for 21 patients were evaluated. The median BMI and APACHE II scores were 37.1 (IQR 28.8–48.9) and 24 (IQR 17.7–31), respectively. The median average daily dose of micafungin was 300 mg (IQR 275–400). Patients were treated with high-dose (HD) micafungin for the entirety of their echinocandin course in 15 encounters (65.2%). Transaminases remained stable, while a trend towards increased alkaline phosphatase was observed. A total of four deaths occurred (17.4%). Patients that died were predominantly young, Hispanic males who were obese and/or critically ill. Future studies are needed to determine the necessity and appropriate placement of HD micafungin in obese and/or critically ill patients.Keywords
This publication has 16 references indexed in Scilit:
- Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit PatientsClinical Pharmacokinetics, 2017
- Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured reviewInternational Journal of Antimicrobial Agents, 2016
- Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002–20121Emerging Infectious Diseases, 2016
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2015
- Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or CandidemiaAntimicrobial Agents and Chemotherapy, 2011
- Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study*Critical Care Medicine, 2011
- Effect of Antifungal Therapy Timing on Mortality in Cancer Patients with CandidemiaAntimicrobial Agents and Chemotherapy, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional StudyClinical Infectious Diseases, 2006
- A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantationBone Marrow Transplantation, 2006